Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Роль фракталкина в патогенезе идиопатической легочной гипертензии - Журнал Системные Гипертензии №2 (2010)
Роль фракталкина в патогенезе идиопатической легочной гипертензии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассматриваются вопросы современной классификации легочной гипертензии, основные механизмы патогенеза заболевания, изложена характеристика иммуновоспалительных изменений и подробно описана роль хемокинов при легочной гипертензии. Накапливаются доказательства (включая приведенные данные собственных исследований) значительной роли фракталкина – единственного хемокина, существующего в растворимой и фиксированной формах, в патогенезе идиопатической легочной гипертензии. Это позволяет рассматривать этот хемокин и его рецептор CX3CR1 в качестве важных маркеров активации воспалительного процесса. Необходимы дальнейшие исследования для оценки возможности использования фракталкина как цели для терапевтических воздействий у пациентов с идиопатической легочной гипертензией.
Ключевые слова: легкие, сердечно-сосудистые заболевания, идиопатическая легочная гипертензия, патогенез, хемокины, цитокины, фракталкин.
Keywords: lungs, cardiovascular disease, idiopathic pulmonary hypertension, pathogenesis, chemokine, cytokine, fractalkine.
Ключевые слова: легкие, сердечно-сосудистые заболевания, идиопатическая легочная гипертензия, патогенез, хемокины, цитокины, фракталкин.
________________________________________________
Keywords: lungs, cardiovascular disease, idiopathic pulmonary hypertension, pathogenesis, chemokine, cytokine, fractalkine.
Полный текст
Список литературы
1. von Romberg, Ernst. ?ber Sklerose der Lungenarterie (in German). Dtsch Arch Klin Med 48: 197–206.
2. Чазова И.Е., Мартынюк Т.В. Идиопатическая легочная гипертензия. В кн.: Респираторная медицина. В 2 т. Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа 2007.
3. Hatano S, Strasser R. Primary pulmonary hypertension. Geneva: World Heath Organization, 1975.
4. Rich S, Rubin LJ, Abenhail L et al. Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6–10, 1998). Geneva: The World Health Organization, 1998.
5. Simonneau G, Gali? N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): S5–12.
6. Simonneau G, Robbins I, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S43–54.
7. Galie N, Hoeper M, Humbert M. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–63.
8. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular patho-biology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S13–24.
9. Hassoun PM, Mouthon L, Barbera JA et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54 (Suppl. 1): S10–9.
10. Morrell N, Adnot S, Archer S et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S20–S31.
11. Li M, Stenmark KR, Shandas R, Tan W. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. J Vasc Res 2009; 46 (6): 561–71.
12. Sanchez O, Sitbon O, Ja?s X et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130 (1): 182–9.
13. Jais X, Launay D, Yaici A et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58 (2): 521–31.
14. Dorfmuller P, Perros F, Balabanian K et al Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358–63.
15. Rich S, Dantzker DR, Ayres SM et al Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216–23.
16. Amany R. Seraga, Sahar M et al. Regulated upon activation, normal T-cell expressed and secreted chemokine and interleukin-6 in rheumatic pulmonary hypertension, targets for therapeutic decisions Eur J Cardiothorac Surg 2010; 37: 853–58.
17. Cool CD, Kennedy D, Voelkel NF, Tuder RF. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunode?ciency virus infection. Human Pathol 1997; 28: 434–42.
18. Okawa-Takatsuji M, Aotsuka S, Fujinami M et al. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116: 174–80.
19. Nicolls MR, Taraseviciene-Stewart L, Rai PR et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005; 26 (6): 1110–8.
20. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and element of in?ammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275–85.
21. Dorfm?ller P, Zarka V, Durand-Gasselin I et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165 (4): 534–9.
22. Sanchez O, Marcos E, Perros F et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007; 176 (10): 1041–7.
23. Bazan JF, Bacon KB, Hardiman G et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385 (6617): 640–4.
24. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276 (41): 37993–8001.
25. Hundhausen C. Misztela D, Berkhout TA et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186–95.
26. Hurst LA, Bunning RA, Couraud PO. Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. J Neuroimmunol 2009; 210 (1–2): 108–12.
27. Fong AM, Robinson LA, Streeber DA et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188: 1413.
28. Green S, Han KH, Chen Y et al. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine /CX3CL1 via p38 MAPK. J Immunol 2006; 176 (12): 7412–20.
29. Murphy G, Caplice N, Molloy M et al. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology (Oxford), 2008.
30. Hyakudomi M, Matsubara T, Hyakudomi R et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 2008; 15 (6): 1775–82.
31. Niessner A, Marculescu R, Kvakan H et al. Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thromb Haemost 2005; 94 (6): 1251–6.
32. Robinson LA, Nataraj C, Thomas DW et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000; 165(11): 6067–72.
33. Yoshida T, Hanawa H, Toba K et al. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 2005; 68 (2): 278–88.
34. Combadiere C, Potteaux S, Gao JL et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003; 107: 1009–16.
35. Chen XJ, Cheng DY, Yang L, Xia XQ. The change of fractalkine in serum and pulmonary arterioles of hypoxic rat. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38 (5): 756–60.
36. Marasini B, Cossutta R., Selmi C et al. Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin Dev Immunol. 2005; 12 (4): 275–9.
37. Balabanian K, Foussat A, Dorfmuller P et al. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Resp Crit Care Med 2002; 165: 1419–25.
38. Perros F, Dorfmuller P, Souza R et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937–43.
39. Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am J Respir Crit Care Med 1995; 151 (5): 1628–31.
40. Garcia GE, Xia Y., Chen S et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000; 67 (4): 577–84.
41. Ludwig A, Berkhout T, Moores K et al. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002; 168 (2): 604–12.
42. Sch?fer A, Schulz C, Fraccarollo D et al. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 2007; 27 (1): 55–62.
43. Yoneda O, Imai T, Goda S et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000; 164 (8): 4055–62.
44. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. Immunol 2007; 179: 7478–87.
45. Nakonechnikov S. Evaluation of the fractalkine level in patients with different genesis of pulmonary hypertension. J Clin Hypertens 2008; 10 (5; Suppl. A): 120.
46. Moon SO, Kim W, Sung MJ et al. Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol Pharmacol 2006; 70 (1): 112–9.
2. Чазова И.Е., Мартынюк Т.В. Идиопатическая легочная гипертензия. В кн.: Респираторная медицина. В 2 т. Под ред. А.Г.Чучалина. М.: ГЭОТАР-Медиа 2007.
3. Hatano S, Strasser R. Primary pulmonary hypertension. Geneva: World Heath Organization, 1975.
4. Rich S, Rubin LJ, Abenhail L et al. Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6–10, 1998). Geneva: The World Health Organization, 1998.
5. Simonneau G, Gali? N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): S5–12.
6. Simonneau G, Robbins I, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S43–54.
7. Galie N, Hoeper M, Humbert M. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–63.
8. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular patho-biology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S13–24.
9. Hassoun PM, Mouthon L, Barbera JA et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54 (Suppl. 1): S10–9.
10. Morrell N, Adnot S, Archer S et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S20–S31.
11. Li M, Stenmark KR, Shandas R, Tan W. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. J Vasc Res 2009; 46 (6): 561–71.
12. Sanchez O, Sitbon O, Ja?s X et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130 (1): 182–9.
13. Jais X, Launay D, Yaici A et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58 (2): 521–31.
14. Dorfmuller P, Perros F, Balabanian K et al Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358–63.
15. Rich S, Dantzker DR, Ayres SM et al Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216–23.
16. Amany R. Seraga, Sahar M et al. Regulated upon activation, normal T-cell expressed and secreted chemokine and interleukin-6 in rheumatic pulmonary hypertension, targets for therapeutic decisions Eur J Cardiothorac Surg 2010; 37: 853–58.
17. Cool CD, Kennedy D, Voelkel NF, Tuder RF. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunode?ciency virus infection. Human Pathol 1997; 28: 434–42.
18. Okawa-Takatsuji M, Aotsuka S, Fujinami M et al. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116: 174–80.
19. Nicolls MR, Taraseviciene-Stewart L, Rai PR et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005; 26 (6): 1110–8.
20. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and element of in?ammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275–85.
21. Dorfm?ller P, Zarka V, Durand-Gasselin I et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165 (4): 534–9.
22. Sanchez O, Marcos E, Perros F et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007; 176 (10): 1041–7.
23. Bazan JF, Bacon KB, Hardiman G et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385 (6617): 640–4.
24. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276 (41): 37993–8001.
25. Hundhausen C. Misztela D, Berkhout TA et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186–95.
26. Hurst LA, Bunning RA, Couraud PO. Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. J Neuroimmunol 2009; 210 (1–2): 108–12.
27. Fong AM, Robinson LA, Streeber DA et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188: 1413.
28. Green S, Han KH, Chen Y et al. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine /CX3CL1 via p38 MAPK. J Immunol 2006; 176 (12): 7412–20.
29. Murphy G, Caplice N, Molloy M et al. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology (Oxford), 2008.
30. Hyakudomi M, Matsubara T, Hyakudomi R et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 2008; 15 (6): 1775–82.
31. Niessner A, Marculescu R, Kvakan H et al. Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thromb Haemost 2005; 94 (6): 1251–6.
32. Robinson LA, Nataraj C, Thomas DW et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000; 165(11): 6067–72.
33. Yoshida T, Hanawa H, Toba K et al. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 2005; 68 (2): 278–88.
34. Combadiere C, Potteaux S, Gao JL et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003; 107: 1009–16.
35. Chen XJ, Cheng DY, Yang L, Xia XQ. The change of fractalkine in serum and pulmonary arterioles of hypoxic rat. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38 (5): 756–60.
36. Marasini B, Cossutta R., Selmi C et al. Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin Dev Immunol. 2005; 12 (4): 275–9.
37. Balabanian K, Foussat A, Dorfmuller P et al. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Resp Crit Care Med 2002; 165: 1419–25.
38. Perros F, Dorfmuller P, Souza R et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937–43.
39. Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am J Respir Crit Care Med 1995; 151 (5): 1628–31.
40. Garcia GE, Xia Y., Chen S et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000; 67 (4): 577–84.
41. Ludwig A, Berkhout T, Moores K et al. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002; 168 (2): 604–12.
42. Sch?fer A, Schulz C, Fraccarollo D et al. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 2007; 27 (1): 55–62.
43. Yoneda O, Imai T, Goda S et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000; 164 (8): 4055–62.
44. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. Immunol 2007; 179: 7478–87.
45. Nakonechnikov S. Evaluation of the fractalkine level in patients with different genesis of pulmonary hypertension. J Clin Hypertens 2008; 10 (5; Suppl. A): 120.
46. Moon SO, Kim W, Sung MJ et al. Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol Pharmacol 2006; 70 (1): 112–9.
Авторы
С.Н.Наконечников, К.А.Зыков, Т.В.Мартынюк, В.П.Масенко, И.Е.Чазова
ФГУ Российский кардиологический научно-производственный комплекс, Москва
FSI Russian cardiology scientific and production complex, Moscow
ФГУ Российский кардиологический научно-производственный комплекс, Москва
________________________________________________
FSI Russian cardiology scientific and production complex, Moscow
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.